Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the authorization of the Pfizer/BioNTech vaccine for use in many children as well as what lies ahead in the vaccine pipeline for the pediatric population.
The news about the Pfizer/BioNTech COVID-19 vaccine becoming available for children aged 5 to 11 years was met with happiness by pediatricians and many parents alike. Vaccines in the pipeline could bring similar happiness if found safe and effective.
Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the authorization of the Pfizer/BioNTech vaccine for use in many children as well as what lies ahead in the vaccine pipeline for the pediatric population.
Infant RSV hospitalization rates 28%, 43% lower this season vs pre-COVID seasons
May 9th 2025"These findings support Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants," wrote the MMWR study investigators.